Trial · NCT07471815
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
NCT07471815, Phase 2, Active not recruiting, Harbin Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy. Trials, record NCT07471815. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07471815
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
- NCT number
- NCT07471815
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Harbin Medical University
- Conditions
- Breast Cancer Triple Negative Breast Cancer
- Interventions
- Camrelizumab + Risedronate Sodium + Chemotherapy
- First posted
- 2026-03-13
- Last updated
- 2026-03-13
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ORR | At the end of every 2 Cycles (each cycle is 21 days), From first treatment Cycle until achieving complete response (CR) or response (PR) per RECIST v1.1, assessed up to 1 year, defined as the proportion of patients achieving complete response | Objective Response Rate |
| Secondary | Incidence of adverse events of any grade | Safety follow-up will be conducted from the first dose until the end of treatment. Adverse events occurring during this period will be recorded, with a maximum assessment period of 2 years. | Incidence of adverse events (AEs) and serious adverse events (SAEs) of any grade, assessed according to NCI-CTCAE version 6.0 criteria. |
| Secondary | OS | Refers to the time from randomization to death due to any cause, with a maximum assessment period of 2 years. | Overall Survival |
| Secondary | 6-PFS Rate | The proportion of patients who have not experienced tumor progression or death from any cause by 6 months from the start of first treatment, with a maximum assessment period of 6 months. | 6-Month Progression-Free Survival Rate |
| Secondary | DOR | Refers to the time from the first assessment of CR or PR to the first assessment of disease progression (PD) or death from any cause. The assessment period is up to 2 years. | Duration of Response |
| Secondary | DCR | Patients undergo imaging evaluation in every 2 cycles（each cycyle is 21 days）until achieving SD per RECIST v1.1 or through study completion, assessed up to 1 year. | Disease Control Rate: Refers to the percentage of patients with evaluable cases who achieve Complete Response (CR), Partial Response (PR), or Stable Disease (SD) following treatment. |
| Secondary | Incidence of new bone metastases | Starting from the first dose, regular imaging follow-ups will be conducted to monitor for the occurrence of bone metastases, continuing until 2 years. | Refers to the ratio of the number of new cases with bone metastases to the total number of cases in the same population during the corresponding period. |
| Secondary | BMD | A key indicator for measuring bone strength, reflecting the mineral content (mainly calcium, phosphorus, etc.) per unit volume or unit area of bone. Assessments will be conducted once every three months for up to 2 year. | Bone Mineral Density |
| Other | Mechanism Exploration | The mechanism of Camrelizumab combined with Risedronate Sodium and chemotherapy, with a maximum follow-up of up to 2 years. | The mechanism of Camrelizumab combined with Risedronate Sodium and chemotherapy |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07471815
GET https://conductscience.org/api/trials/v1/NCT07471815/registered